9789811001246-9811001243-Frontiers of Biostatistical Methods and Applications in Clinical Oncology

Frontiers of Biostatistical Methods and Applications in Clinical Oncology

ISBN-13: 9789811001246
ISBN-10: 9811001243
Edition: 1st ed. 2017
Publication date: 2017
Publisher: Springer
Format: Hardcover 451 pages
FREE shipping on ALL orders

Book details

ISBN-13: 9789811001246
ISBN-10: 9811001243
Edition: 1st ed. 2017
Publication date: 2017
Publisher: Springer
Format: Hardcover 451 pages

Summary

Acknowledged author wrote Frontiers of Biostatistical Methods and Applications in Clinical Oncology comprising 451 pages back in 2017. Textbook and eTextbook are published under ISBN 9811001243 and 9789811001246. Since then Frontiers of Biostatistical Methods and Applications in Clinical Oncology textbook was available to sell back to BooksRun online for the top buyback price or rent at the marketplace.

Description

This book presents the state of the art of biostatistical methods and their applications in clinical oncology. Many methodologies established today in biostatistics have been brought about through its applications to the design and analysis of oncology clinical studies. This field of oncology, now in the midst of evolution owing to rapid advances in biotechnologies and cancer genomics, is becoming one of the most promising disease fields in the shift toward personalized medicine. Modern developments of diagnosis and therapeutics of cancer have also been continuously fueled by recent progress in establishing the infrastructure for conducting more complex, large-scale clinical trials and observational studies. The field of cancer clinical studies therefore will continue to provide many new statistical challenges that warrant further progress in the methodology and practice of biostatistics. This book provides a systematic coverage of various stages of cancer clinical studies. Topics from modern cancer clinical trials include phase I clinical trials for combination therapies, exploratory phase II trials with multiple endpoints/treatments, and confirmative biomarker-based phase III trials with interim monitoring and adaptation. It also covers important areas of cancer screening, prognostic analysis, and the analysis of large-scale molecular data in the era of big data.

Rate this book Rate this book

We would LOVE it if you could help us and other readers by reviewing the book